Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Enterobacteriaceae is a large family of Gram-negative, rod-shaped (bacilli) bacteria in the order Enterobacterales, class Gammaproteobacteria. They are characterized by their facultatively anaerobic metabolism, ability to ferment glucose, and presence of various antigens (O, H, K) used in serotyping. Members of this family are ubiquitous in nature, commonly found as commensals in the intestines of animals, but several genera—such as Escherichia, Klebsiella, Salmonella, Shigella, Enterobacter, Citrobacter, Proteus, Serratia, and Yersinia—are important human pathogens causing a broad range of community-acquired and healthcare-associated infections, including urinary tract infections, gastrointestinal disease, pneumonia, and sepsis. Increasing prevalence of antibiotic resistance, especially carbapenem-resistant Enterobacteriaceae (CRE), presents significant therapeutic challenges.
Disruption of bacterial cell wall synthesis (β-lactam antibiotics, e.g. cephalosporins, carbapenems); Inhibition of DNA replication (fluoroquinolones); Inhibition of protein synthesis (aminoglycosides); Disruption of folate metabolism (sulfonamides)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Enterobacteriaceae.